Pub. Date:
Springer-Verlag New York, LLC
Combination Cancer Therapy: Modulators and Potentiators / Edition 1

Combination Cancer Therapy: Modulators and Potentiators / Edition 1

by Gary K. SchwartzGary K. Schwartz
Current price is , Original price is $219.99. You

Temporarily Out of Stock Online

Please check back later for updated availability.

1 New & Used Starting at $211.24


Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatments in cancer therapy.

Product Details

ISBN-13: 9781627038065
Publisher: Springer-Verlag New York, LLC
Publication date: 11/25/2014
Series: Cancer Drug Discovery and Development
Edition description: 2005
Pages: 284
Product dimensions: 6.10(w) x 9.25(h) x 0.02(d)

Table of Contents

Targeting of the EGFR As a Modulator of Cancer Chemotherapy
Jose Baselga

Cyclin-Dependent Kinase Inhibitors in Combination Chemotherapy
Manish A. Shah and Gary K. Schwartz

Development of Protein Kinase C and Cyclin-Dependent Kinase Inhibitors As Potentiators of Cytotoxic Drug Action in Leukemia
Steven Grant

Carboxyamidotriazole, an Inhibitor of Nonvoltage-Operated Calcium Entry: Single-Agent and Combination Therapy for Ovarian Carcinoma
Chad M. Michener and Elise C. Kohn

Targeted a-Particle Therapy: A Rational Approach to Drug Development in Hematologic Diseases and Solid Tumors
John M. Burke, David A. Scheinberg, and Joseph G. Jurcic

Pharmacological Modulation of Fluoropyrimidines: Building on the Lessons of the Past
Owen A. O'Connor

Development of Inhibitors of HER2 With Taxanes: New Directions in Breast Cancer Therapy
Shanu Modi, Monica N. Fornier, and Andrew D. Seidman

Targeting NF-kB to Increase the Activity of Cisplatin in Solid Tumors
Don S. Dizon, Carol Aghajanian, X. Jun Yan, and David R. Spriggs

Combinations of Chemotherapy and G3139, an Antisense Bcl-2 Oligonucleotide
Luba Benimetskaya, Sridhar Mani, and C. A. Stein

Use of Animal Models to Evaluate Signal Transduction Inhibitors As Modulators of Cytotoxic Therapy
Beverly A. Teicher


Customer Reviews

Most Helpful Customer Reviews

See All Customer Reviews